Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 7,413 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Tissue specimen Clear all

Conditions: Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer, Genitourinary Cancer, Sarcoma, Breast Cancer, Colon Cancer, Gastrointestinal Cancer, Solid Tumor Cancer, Lung Cancer, Skin Cancer, Melanoma
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With Minimal Differentiation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Adult Erythroleukemia, Adult Pure Erythroid Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Recurrent Adult Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Azacitidine, Busulfan, Fludarabine Phosphate, Laboratory Biomarker Analysis, Methotrexate, Pharmacological Study, Tacrolimus; Procedure · Biological · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 74 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 17
States / cities: Lewes, Delaware • Newark, Delaware • Orlando, Florida + 12 more

Conditions: Prostate Cancer
Interventions: Leuprolide acetate, Bicalutamide, Sorafenib; Drug
Lead sponsor: Beth Israel Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Anterior Cruciate Ligament Injuries, Anterior Cruciate Ligament Rupture, Anterior Cruciate Ligament Tear
Interventions: ACL Reconstruction; Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 19 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Congenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia, Leukemia, Myelodysplastic Syndromes, Severe Congenital Neutropenia
Interventions: alemtuzumab, busulfan, cyclosporine, fludarabine phosphate, methotrexate, methylprednisolone, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, umbilical cord blood transplantation; Biological · Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: Up to 21 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 2
States / cities: San Francisco, California • Madison, Wisconsin

Conditions: Hand Hygiene Effectiveness
Interventions: hand antiseptic with CHG and alcohol, Alcohol hand sanitizer foam; Drug
Lead sponsor: Solventum US LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Wound of Skin
Interventions: MIST Therapy, Standard of Care; Device · Other
Lead sponsor: Celleration, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Glioma, Glioma, Malignant, Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, GBM, Brain Cancer, High Grade Glioma
Interventions: Laparoscopically harvested omental tissue autograft; Procedure
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Low Back Pain (CLBP)
Interventions: Dry needling; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Liver Cancer, Hepatobiliary Tract Adenomas and Carcinomas
Interventions: Hepatocellular carcinoma; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 70 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Pentalogy of Cantrell
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Up to 100 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2019
U.S. locations: 2
States / cities: Bethesda, Maryland • Houston, Texas

Conditions: Graft -Versus-host-disease
Interventions: Hematopoietic Cell Transplantation, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil (MMF), Axatilimab; Procedure · Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Pulmonary Hypertension, Systemic Sclerosis, Mixed Connective Tissue Disease, Heart Failure With Normal Ejection Fraction, Healthy
Interventions: No intervention. Biospecimen collection only; Other
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Pulmonary Hypertension
Interventions: Treprostinil, Standard of Care; Drug · Other
Lead sponsor: Valley Health System; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Paramus, New Jersey

Conditions: Lymphoma
Interventions: apolizumab; Biological
Lead sponsor: PDL BioPharma, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Freemont, California

Conditions: Trauma Injury, Trauma, Critical Illness, Microbiome, Chronic Anemia, Acute Blood Loss Anemia
Interventions: Data and tissue collection; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Gainesville, Florida

Conditions: 714leukemia, Lymphoma
Interventions: Bortezomib, Everolimus; Drug
Lead sponsor: Brian Hill, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Lymphoma
Interventions: denileukin diftitox; Biological
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 10
States / cities: Chicago, Illinois • Boston, Massachusetts • Las Vegas, Nevada + 7 more

Conditions: Leukoplakia, Erythroplakia
Interventions: PDL-585, ScleroPLUS laser, 5-Aminolevulinic Acid (Levulan KerastickTM), Fluorescence Diagnosis Imaging; Device · Drug · Procedure
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: MDx Health; Industry
Eligibility: 40 Years to 75 Years · Male only
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 15
States / cities: Homewood, Alabama • San Diego, California • Torrance, California + 12 more

Conditions: Postmenopausal, Breast Cancer
Interventions: Acupressure; Other
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Egg Donation
Interventions: Follistim, Ganirelix, Menotropins, Leuprolide, Transvaginal ultrasound guided needle aspiration of oocytes; Drug · Procedure
Lead sponsor: Michigan Reproductive Medicine; Other
Eligibility: 18 Years to 28 Years · Female only
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Bloomfield Hills, Michigan

Conditions: Peripheral Artery Disease, PAD, Claudication, Peripheral Vascular Disease, PVD
Interventions: Stealth 360°® OAS; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Mitral Insufficiency
Interventions: Pressure volume loop evaluation, cardiovascular magnetic resonance imaging, Cardiopulmonary exercise testing (CPET), Kansas City Cardiomyopathy Questionairre; Diagnostic Test
Lead sponsor: Atlantic Health System; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Morristown, New Jersey

Search by objective public record fields.

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia

Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer

Tendon-Bone Versus All-Soft-Tissue for ACL Reconstruction: A Patient-Blinded Randomized Clinical Trial

Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders

Evaluation of Two Hand Hygiene Products in ICUs

Deep Tissue Injury Treatment With MIST Therapy Versus Standard Care: REVERSE DTI Study

Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)

A Mediation Analysis Investigating Dry Needling Treatment Mechanisms in a Chronic Low Back Pain Population

Observational Study of Biomarker During Liver Surgery

Mutations in Genes Associated With Pentalogy of Cantrell

CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation

New Orleans Pulmonary Hypertension Biobank

Early Intervention With Inhaled Treprostinil Among Patients With Exercise-Induced Pulmonary Hypertension (EPIH)

Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

The Role of Brain-Bone Marrow-Gut Interaction Following Major Trauma

Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma

Treatment of Oral Premalignant Lesions With 5-ALA PDT

PASCUAL (Prostate Assay Specific Clinical Utility at Launch) Study

Acupressure for Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Patients With Breast Cancer

Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation

Tissue Removal Assessment With Ultrasound of THe SFA and Popliteal

Assessing the Relationship Between Symptoms and Mitral Regurgitnant. Severity